Author

Lauren Whelan

The University of Melbourne

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 4 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Assay:CRISPR screen· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:statistical model· 2

Frequent Co-Authors

Andrew J. KuehiD· 3 shared Lin TaiiD· 3 shared Marco J. HeroldiD· 3 shared Margaret A. PottsiD· 3 shared Andreas StrasseriD· 2 shared Annabella ThomasiD· 2 shared Benjamin HaleyiD· 2 shared Christina KoenigiD· 2 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Andrew J. KuehORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

A novel, high-density CRISPR activation platform for mapping cancer dependencies and resistance pathways ex vivo and in vivo

Sarah T. Diepstraten, Yexuan Deng, Margaret A. Potts, Amy J. Heidersbach, Christina Koenig, Kristel M. Dorighi, Lin Tai, Andrew J. Kueh, Lauren Whelan, Catherine W.T. Chang, Felix Brown, Gemma L. Kelly, Jean‐Philippe Fortin, Benjamin Haley, John E. La Marca, Marco J. Herold

This paper introduces Partita, a high-density CRISPRa platform for comprehensive gene activation studies, demonstrating its utility in identifying cancer dependencies and resistance pathways in vitro and in vivo.

Science Advances · Sep 18, 2026Peer-reviewedCancer Biology

Pre-existing levels of pro-survival proteins and induction of BCL-XL dictate cell fate after p53 activation

Allan Shuai Huang, Elizabeth Lieschke, Pedro L. Baldoni, Annabella Thomas, Julia M. Marchingo, Lauren Whelan, Grace Khuu, Eddie La Marca, Michael J. G. Milevskiy, Aisling M. Ross, Timothy M. Johanson, Margaret A. Potts, Leonie Gibson, Vineet Vaibhav, Laura F. Dagley, , Andreas Strasser

The paper shows that pre-existing levels of pro-survival proteins and BCL-XL induction determine cell fate after p53 activation, with implications for cancer therapy.

bioRxiv · Jul 2, 2026 · PreprintCancer Biology

Transcriptomic alterations including p53 pathway dysregulation prime DNMT3A mutant cells for transformation

Erin Lawrence, Amali Cooray, Andrew J. Kueh, Martin Pál, Lin Tai, Alexandra L. Garnham, Connie S.N. Li Wai Suen, Hannah Kate Vanyai, Quentin A. Gouil, James Lancaster, Sylvie Callegari, Lauren Whelan, Elizabeth Lieschke, Annabella Thomas, Andreas Strasser, , Marco J. Herold

This study shows DNMT3A mutations reduce DNA methylation and disrupt p53 pathway, increasing self-renewal and cancer risk in hematopoietic cells.

EMBO Reports · Apr 30, 2025Peer-reviewedCancer Biology

Advancing the genetic engineering toolbox by combining AsCas12a knock-in mice with ultra-compact screening

Wei Jin, Yexuan Deng, John E. La Marca, Emily J. Lelliott, Sarah T. Diepstraten, Christina Koenig, Lin Tai, Valentina Snetkova, Kristel M. Dorighi, Luke Hoberecht, Millicent G. Hedditch, Lauren Whelan, Geraldine Healey, Dan Fayle, Kieran Lau, , Marco J. Herold

The paper introduces an enAsCas12a mouse model and associated libraries for efficient gene editing and screening, identifying drug resistance genes and enabling simultaneous gene knockouts and activations.

Nature Communications · Jan 30, 2025Peer-reviewedMolecular Biology